RAC1 and melanoma: As statins have been shown to prevent Rac1 isoprenylation 15 and to inhibit the Rho-pathway 15,19, it might be possible that males have worse survival rates than females due to a higher rate of Rac1 mutations leading to an increased activity of the Rho-pathway in male melanoma cells, which in turn might be counteracted by statin use.